ADA: Once-Weekly Cagrilintide + Semaglutide Promising in Type 2 Diabetes FRIDAY, June 12, 2026 -- Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose cotransporter 2 inhibitor (SGLT2i), and using basal insulin, according to three studies published online June 7 in The Lancet Diabetes & Endocrinology and The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans
These gastrointestinal issues could be fatal without urgent medical attention
Without resistance training and adequate movement, up to one-third of weight lost on GLP-1 medications may come from lean muscle
Synthetically scalable poly(ampholyte) which dramatically enhances cellular cryopreservation
By stabilizing glucose levels, semaglutide reduces the energy crashes and cravings that sabotage PCOS management efforts
An improved protocol for the treatment of fulminant myocarditis
